GLP-1 receptor agonists (GLP-1 RA) represent a promising disease-modifying approach for Parkinson's disease. Originally developed for type 2 diabetes, these agents show neuroprotective effects through multiple mechanisms.
- Status: Phase 2 completed, Phase 3 planned
- Trial: NCT01971242 (completed)
- Results: Showed improvement in motor scores vs. placebo
- Mechanism: GLP-1 receptor activation in substantia nigra
- Status: Phase 2 ongoing
- Trial: NCT02953665
- Focus: Neuroprotection in early PD
- Status: Planning Phase 2/3 trials
- Rationale: Higher brain penetration than earlier GLP-1 RAs
GLP-1 receptors are expressed in the brain, particularly in:
- Mitochondrial function: Enhanced ATP production, reduced ROS
- Anti-inflammatory: Reduced microglial activation
- Synaptic protection: Improved synaptic plasticity
- Autophagy: Enhanced clearance of damaged proteins
- Anti-apoptotic: Reduced neuronal death
- Improved MDS-UPDRS motor scores
- Effects persisted after drug discontinuation
- Well-tolerated side effect profile
- ClinicalTrials.gov: Exenatide PD
- ClinicalTrials.gov: Liraglutide PD